当前位置: X-MOL 学术Eur. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
European Urology ( IF 25.3 ) Pub Date : 2024-10-11 , DOI: 10.1016/j.eururo.2024.09.017
Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Ana Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Aurelius Omlin

Background and objective

Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024.

Methods

Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members (“panellists”).

Key findings and limitations

Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis.

Conclusions and clinical implications

The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.


中文翻译:


晚期前列腺癌患者的管理。2024 年晚期前列腺癌共识会议 (APCCC) 报告


 背景和目标


创新改善了晚期前列腺癌 (PC) 的预后。尽管如此,我们仍然缺乏关于对日常实践产生重大影响的各种主题的高水平证据。2024 年晚期前列腺癌共识会议 (APCCC) 就临床管理中的关键问题对专家进行了调查,以补充循证指南。在这里,我们展示了 APCCC 2024 问题的投票结果。

 方法


在会议之前,一个由 120 名国际 PC 专家组成的小组使用修改后的 Delphi 流程,就 8 个不同的主题开发了 183 个多项选择共识问题。在会议之前,这些问题是通过基于网络的调查对投票小组成员(“小组成员”)进行的。


主要发现和局限性


共识是先验定义为 ≥75% 的一致性,强共识定义为 ≥90% 的一致性。投票结果显示了不同程度的共识,如本文所述,并在补充材料中进行了详细说明。这些发现不包括正式的文献综述或荟萃分析。


结论和临床意义


投票结果可以帮助医生和患者了解临床管理中缺乏高水平证据或相互矛盾的有争议的领域。这些发现还可以帮助资助者和政策制定者确定未来研究领域的优先顺序。诊断和治疗决策应始终根据患者和癌症特征进行个体化,并应结合当前和新出现的临床证据、指南以及物流和经济因素。始终强烈鼓励参加临床试验。重要的是,APCCC 2024 再次确定了值得在专门设计的试验中进行评估的重要差距(未达成共识的领域)。
更新日期:2024-10-11
down
wechat
bug